Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2026)

Moderna has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $147.0 million in Q2 2026.

• Non-Current Deffered Revenue for Q2 2026 came in at $147.0 million, up 126.15% year-over-year; the trailing twelve-month figure through Jun 2026 was $147.0 million (up 126.15% YoY), and the FY2025 annual result was $153.0 million, up 163.79% from the prior year.
• Non-Current Deffered Revenue declined to $147.0 million in Q2 2026, from $154.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $692.0 million in Q2 2023 and troughed at $58.0 million in Q1 2024.
• A 5-year average of $242.8 million and a median of $153.5 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The widest annual swing landed in 2024, when Non-Current Deffered Revenue tumbled 91.38%; it then surged 165.52% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $673.0 million in 2022, then plunged by 87.67% to $83.0 million in 2023, then sank by 30.12% to $58.0 million in 2024, then jumped by 163.79% to $153.0 million in 2025, then fell by 3.92% to $147.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $147.0 million in Q2 2026, $154.0 million in Q1 2026, and $153.0 million in Q4 2025.